15 August 2024
Mind Your Business: A simple blood test is revolutionising cancer treatment
Singapore is emerging as a global leader in cancer research, with a strong focus on genomics and personalised treatments.
We want to explore how local innovation is transforming cancer care with a pioneering healthtech company that has developed a groundbreaking multi-cancer early detection tool.
Dr Min-Han Tan, Founder, CEO and Medical Director, Lucence shares how they are collaborating with physicians, impacting patient lives, and shaping the future of cancer treatment. We'll also examine the broader economic implications of Singapore's biomedical industry.
Presented by Emaad Akhtar
This podcast is produced and edited by Anthea Ng (nganthea@sph.com.sg)
She produces Mind Your Business, Biz-How-To and Breakfast Special segments on the Breakfast Show.
Do contact her for topics: C-Suite, SME, Startups, Health-tech, Sustainability, Property, Intergenerational Family Business, Industry Outlook, Fintech and trending businesses in town.

Download this podcast.

Listen To His Previous Podcasts:

24 February 2023
Under the Radar: Lucence’s take on the global cancer diagnostics market surpassing US$258.54b by 2030, Its LiquidHALLMARK cancer detection blood test, treading the fine line between pricing products affordably and achieving business objectives
Are you afraid of having your blood drawn? But what if the blood test could detect cancer causing genetic mutations and viruses, and allow for early treatment?
I’m asking this because we are going to look at a company called Lucence, which makes blood tests to detect cancers.
Founded in 2016, Lucence was spun off from the Agency for Science, Technology and Research (A*STAR).
It had in 2019 unveiled a blood test called LiquidHALLMARK that detects 14 types of cancers, 50 genetic mutations and two viruses. Lucence had said then that LiquidHALLMARK is the world's first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9 per cent accuracy.
But how much money does this represent? How does the company assess its competition, and how is it treading the fine line in ensuring that it achieves the profits it wants yet ensure that the tests remain affordable and accessible?
On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these burning questions to Dr Tan Min-Han Founder, CEO and Medical Director at Lucence.

Download this podcast.